Paul Streck Biography and Net Worth

Executive Vice President, Head of Research & Development of PepGen

Paul Streck serves as Executive Vice President, Head of Research & Development at PepGen. Prior to joining PepGen, he served as Chief Medical Officer at Albireo Pharma, a publicly traded rare disease biotechnology company acquired by Ipsen in March 2023. Previously, Paul was Chief Medical Officer at Arena Pharmaceuticals, a publicly traded immuno-inflammatory biotechnology company acquired by Pfizer in March 2022. Before that, he served as Chief Medical Officer at Alder Biopharmaceuticals, acquired by Lundbeck Pharmaceuticals in October 2020, and as the Chief Medical Officer of Insmed, advancing the company from clinical to commercial stage. Previous biopharmaceutical experience includes progressive roles at GSK, Shire, and Amgen, as well as 10 years in academic medical practice. Paul received his MBA from Duke University Fuqua School of Business, his MD from Jefferson Medical College, his DMD from Temple University School of Dentistry, and his BA in Chemistry from Rutgers University.

What is Paul Streck's net worth?: The estimated net worth of Paul Streck is at least $77.71 thousand as of May 30th, 2025. Mr. Streck owns 27,805 shares of PepGen stock worth more than $77,715 as of August 7th. This net worth approximation does not reflect any other assets that Mr. Streck may own. Learn More about Paul Streck's net worth.
How do I contact Paul Streck?: The corporate mailing address for Mr. Streck and other PepGen executives is , , . PepGen can also be reached via phone at 781-797-0979 and via email at [email protected]. Learn More on Paul Streck's contact information.
Has Paul Streck been buying or selling shares of PepGen?: Paul Streck has not been actively trading shares of PepGen during the past quarter. Most recently, on Friday, May 30th, Paul Streck bought 8,375 shares of PepGen stock. The stock was acquired at an average cost of $1.24 per share, with a total value of $10,385.00. Following the completion of the transaction, the executive vice president now directly owns 27,805 shares of the company's stock, valued at $34,478.20. Learn More on Paul Streck's trading history.
Who are PepGen's active insiders?: PepGen's insider roster includes Kasra Kasraian (Revisit consent button Skip to Content PepGen Menu About Science EDO Platform Scientific Pub), James McArthur (President and Chief Executive Officer), and Paul Streck (Executive Vice President, Head of Research & Development). Learn More on PepGen's active insiders.
Are insiders buying or selling shares of PepGen?: During the last year, PepGen insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $640,000.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,233 shares worth more than $1,738.53. The most recent insider tranaction occured on May, 21st when insider Kasra Kasraian sold 1,233 shares worth more than $1,738.53. Insiders at PepGen own 1.3% of the company. Learn More about insider trades at PepGen.
Information on this page was last updated on 5/21/2026.

Paul Streck Insider Trading History at PepGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/30/2025	Buy	8,375	$1.24	$10,385.00	27,805

Paul Streck Buying and Selling Activity at PepGen

PepGen Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Today's Range

Now: $2.85

$2.44

$2.87

50 Day Range

MA: $1.84

$1.35

$2.44

2 Week Range

Now: $2.85

$1.01

$7.80

Volume

2,779,705 shs

Average Volume

1,089,213 shs

Market Capitalization

$196.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89